PHD3 affects gastric cancer progression by negatively regulating HIF1A

Xia,Ying‑Jie; Jiang,Xiao‑Ting; Jiang,Shi‑Bin; He,Xu‑Jun; Luo,Jun‑Gang; Liu,Zheng‑Chuang; Wang,Liang; Tao,Hou‑Quan; Chen,Jian‑Zhong

doi:10.3892/mmr.2017.7455

PHD3 affects gastric cancer progression by negatively regulating HIF1A

Authors:
- Ying‑Jie Xia
- Xiao‑Ting Jiang
- Shi‑Bin Jiang
- Xu‑Jun He
- Jun‑Gang Luo
- Zheng‑Chuang Liu
- Liang Wang
- Hou‑Quan Tao
- Jian‑Zhong Chen
View Affiliations

Affiliations: Institute of Immunology, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China, Key Laboratory of Gastroenterology of Zhejiang, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China, Department of Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China
Published online on: September 11, 2017 https://doi.org/10.3892/mmr.2017.7455
Pages: 6882-6889

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prolyl hydroxylase 3 (PHD3) is widely accepted as a tumor suppressor; however, the expression of PHD3 in various cancer types remains controversial. The present study aimed to investigate the association between PHD3 expression and the clinicopathological features of gastric cancer using reverse transcription‑quantitative polymerase chain reaction and immunohistochemistry. The effects of PHD3 in gastric cancer cell lines were assessed using western blot analysis and transwell migration assays. The present results revealed that PHD3 expression was increased in adjacent non‑cancerous tissue compared with in gastric cancer tissue, and PHD3 overexpression was correlated with the presence of well‑differentiated cancer cells, early cancer stage classification and the absence of lymph node metastasis. In vitro experiments demonstrated that PHD3 may act as a negative regulator of hypoxia‑inducible factor‑1α and vascular endothelial growth factor, both of which participate in tumor angiogenesis. In conclusion, the present results suggested that PHD3 may act as a tumor suppressor in gastric cancer. Therefore, the targeted regulation of PHD3 may have potential as a novel therapeutic approach for the treatment of patients with gastric cancer.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Baniak N, Senger JL, Ahmed S, Kanthan SC and Kanthan R: Gastric biomarkers: A global review. World J Surg Oncol. 14:2122016. View Article : Google Scholar : PubMed/NCBI
3	Muz B, de la Puente P, Azab F and Azab AK: The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 3:83–92. 2015. View Article : Google Scholar : PubMed/NCBI
4	Guo X, Li D, Chen Y, An J, Wang K, Xu Z, Chen Z and Xing J: SNP rs2057482 in HIF1A gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery. Sci Rep. 5:118462015. View Article : Google Scholar : PubMed/NCBI
5	Fraga A, Ribeiro R, Principe P, Lobato C, Pina F, Maurício J, Monteiro C, Sousa H, da Silva F Calais, Lopes C and Medeiros R: The HIF1A functional genetic polymorphism at locus +1772 associates with progression to metastatic prostate cancer and refractoriness to hormonal castration. Eur J Cancer. 50:359–365. 2014. View Article : Google Scholar : PubMed/NCBI
6	Shyu KG, Hsu FL, Wang MJ, Wang BW and Lin S: Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion. Exp Cell Res. 313:1181–1191. 2007. View Article : Google Scholar : PubMed/NCBI
7	Zhang W, Zhang H and Xing L: Antisense oligonucleotide of hypoxia-inducible factor-1alpha suppresses growth and tumorigenicity of lung cancer cells A549. J Huazhong Univ Sci Technolog Med Sci. 26:448–450. 2006. View Article : Google Scholar : PubMed/NCBI
8	Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS and Ogino S: HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 176:2292–2301. 2010. View Article : Google Scholar : PubMed/NCBI
9	Espinosa I, José Carnicer M, Catasus L, Canet B, D'angelo E, Zannoni GF and Prat J: Myometrial invasion and lymph node metastasis in endometrioid carcinomas: Tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am J Surg Pathol. 34:1708–1714. 2010.PubMed/NCBI
10	Deb S, Johansson I, Byrne D, Nilsson C, Investigators k Constable L, Fjällskog ML, Dobrovic A, Hedenfalk I and Fox S: Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. Mod Pathol. 27:1223–1230. 2014. View Article : Google Scholar : PubMed/NCBI
11	Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R, et al: High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia. 10:674–679. 2008. View Article : Google Scholar : PubMed/NCBI
12	Vainrib M, Golan M, Amir S, Dang DT, Dang LH, Bar-Shira A, Orr-Urtreger A, Matzkin H and Mabjeesh NJ: HIF1A C1772T polymorphism leads to HIF-1α mRNA overexpression in prostate cancer patients. Cancer Biol Ther. 13:720–726. 2012. View Article : Google Scholar : PubMed/NCBI
13	Nakai H, Watanabe Y, Ueda H and Hoshiai H: Hypoxia inducible factor 1-alpha expression as a factor predictive of efficacy of taxane/platinum chemotherapy in advanced primary epithelial ovarian cancer. Cancer Lett. 251:164–167. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL and Simons JW: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 59:5830–5835. 1999.PubMed/NCBI
15	Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ and Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 157:411–421. 2000. View Article : Google Scholar : PubMed/NCBI
16	Minervini G, Quaglia F and Tosatto SC: Insights into the proline hydroxylase (PHD) family, molecular evolution and its impact on human health. Biochimie. 116:114–124. 2015. View Article : Google Scholar : PubMed/NCBI
17	Place TL, Fitzgerald MP, Venkataraman S, Vorrink SU, Case AJ, Teoh ML and Domann FE: Aberrant promoter CpG methylation is a mechanism for impaired PHD3 expression in a diverse set of malignant cells. PLoS One. 6:e146172011. View Article : Google Scholar : PubMed/NCBI
18	Zhou Y, Liang QL, Ou WT, Liu QL, Zhang XN, Li ZY and Huang X: Effect of stable transfection with PHD3 on growth and proliferation of HepG2 cells in vitro and in vivo. Int J Clin Exp Med. 7:2197–2203. 2014.PubMed/NCBI
19	Chen Y, Zhang HS, Fong GH, Xi QL, Wu GH, Bai CG, Ling ZQ, Fan L, Xu YM, Qin YQ, et al: PHD3 Stabilizes the Tight Junction Protein Occludin and Protects Intestinal Epithelial Barrier Function. J Biol Chem. 290:20580–20589. 2015. View Article : Google Scholar : PubMed/NCBI
20	Liu QL, Liang QL, Li ZY, Zhou Y, Ou WT and Huang ZG: Function and expression of prolyl hydroxylase 3 in cancers. Arch Med Sci. 9:589–593. 2013. View Article : Google Scholar : PubMed/NCBI
21	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
22	Rawluszko AA, Bujnicka KE, Horbacka K, Krokowicz P and Jagodzinski PP: Expression and DNA methylation levels of prolyl hydroxylases PHD1, PHD2, PHD3 and asparaginyl hydroxylase FIH in colorectal cancer. BMC Cancer. 13:5262013. View Article : Google Scholar : PubMed/NCBI
23	Peurala E, Koivunen P, Bloigu R, Haapasaari KM and Jukkola-Vuorinen A: Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 133:179–188. 2012. View Article : Google Scholar : PubMed/NCBI
24	Chen S, Zhang J, Li X, Luo X, Fang J and Chen H: The expression of prolyl hydroxylase domain enzymes are up-regulated and negatively correlated with Bcl-2 in non-small cell lung cancer. Mol Cell Biochem. 358:257–263. 2011. View Article : Google Scholar : PubMed/NCBI
25	Su Y, Loos M, Giese N, Hines OJ, Diebold I, Görlach A, Metzen E, Pastorekova S, Friess H and Büchler P: PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer. Br J Cancer. 103:1571–1579. 2010. View Article : Google Scholar : PubMed/NCBI
26	Tennant DA and Gottlieb E: HIF prolyl hydroxylase-3 mediates alpha-ketoglutarate-induced apoptosis and tumor suppression. J Mol Med (Berl). 88:839–849. 2010. View Article : Google Scholar : PubMed/NCBI
27	Xue J, Li X, Jiao S, Wei Y, Wu G and Fang J: Prolyl hydroxylase-3 is down-regulated in colorectal cancer cells and inhibits IKKbeta independent of hydroxylase activity. Gastroenterology. 138:606–615. 2010. View Article : Google Scholar : PubMed/NCBI
28	Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT and Bremnes RM: Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One. 6:e238472011. View Article : Google Scholar : PubMed/NCBI
29	Couvelard A, Deschamps L, Rebours V, Sauvanet A, Gatter K, Pezzella F, Ruszniewski P and Bedossa P: Overexpression of the oxygen sensors PHD-1, PHD-2, PHD-3, and FIH Is associated with tumor aggressiveness in pancreatic endocrine tumors. Clin Cancer Res. 14:6634–6639. 2008. View Article : Google Scholar : PubMed/NCBI
30	Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, Lobo DN, Harris AL and Madhusudan S: Expression of key hypoxia sensing prolyl-hydroxylases PHD1, −2 and −3 in pancreaticobiliary cancer. Histopathology. 56:908–920. 2010. View Article : Google Scholar : PubMed/NCBI
31	Tanaka T, Li TS, Urata Y, Goto S, Ono Y, Kawakatsu M, Matsushima H, Hirabaru M, Adachi T, Kitasato A, et al: Increased expression of PHD3 represses the HIF-1 signaling pathway and contributes to poor neovascularization in pancreatic ductal adenocarcinoma. J Gastroenterol. 50:975–983. 2015. View Article : Google Scholar : PubMed/NCBI
32	Rishi MT, Selvaraju V, Thirunavukkarasu M, Shaikh IA, Takeda K, Fong GH, Palesty JA, Sanchez JA and Maulik N: Deletion of prolyl hydroxylase domain proteins (PHD1, PHD3) stabilizes hypoxia inducible factor-1 alpha, promotes neovascularization and improves perfusion in a murine model of hind-limb ischemia. Microvasc Res. 97:181–188. 2015. View Article : Google Scholar : PubMed/NCBI
33	Spanberger T, Berghoff AS, Dinhof C, Ilhan-Mutlu A, Magerle M, Hutterer M, Pichler J, Wöhrer A, Hackl M, Widhalm G, et al: Extent of peritumoral brain edema correlates with prognosis, tumoral growth pattern, HIF1a expression and angiogenic activity in patients with single brain metastases. Clin Exp Metastasis. 30:357–368. 2013. View Article : Google Scholar : PubMed/NCBI
34	Lee JW, Bae SH, Jeong JW, Kim SH and Kim KW: Hypoxia-inducible factor (HIF-1)alpha: Its protein stability and biological functions. Exp Mol Med. 36:1–12. 2004. View Article : Google Scholar : PubMed/NCBI